In last trading session, Cardiff Oncology Inc (NASDAQ:CRDF) saw 1.67 million shares changing hands with its beta currently measuring 1.95. Company’s recent per share price level of $2.90 trading at $0.11 or 3.94% at ring of the bell on the day assigns it a market valuation of $135.00M. That closing price of CRDF’s stock is at a discount of -121.38% from its 52-week high price of $6.42 and is indicating a premium of 67.59% from its 52-week low price of $0.94. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.51 million shares which gives us an average trading volume of 453.67K if we extend that period to 3-months.
For Cardiff Oncology Inc (CRDF), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.27 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Upright in the green during last session for gaining 3.94%, in the last five days CRDF remained trading in the green while hitting it’s week-highest on Friday, 10/18/24 when the stock touched $2.90 price level, adding 10.49% to its value on the day. Cardiff Oncology Inc’s shares saw a change of 95.95% in year-to-date performance and have moved 10.27% in past 5-day. Cardiff Oncology Inc (NASDAQ:CRDF) showed a performance of 14.62% in past 30-days. Number of shares sold short was 6.83 million shares which calculate 14.11 days to cover the short interests.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Statistics highlight that Cardiff Oncology Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -33.33% of value to its shares in past 6 months, showing an annual growth rate of -8.60% while that of industry is 17.20. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 8.60% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 80k for the same. And 5 analysts are in estimates of company making revenue of 80k in the next quarter. Company posted 141k and 156k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 35.42% during past 5 years.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Insiders are in possession of 7.25% of company’s total shares while institution are holding 28.74 percent of that, with stock having share float percentage of 30.99%. Investors also watch the number of corporate investors in a company very closely, which is 28.74% institutions for Cardiff Oncology Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CRDF for having 2.63 million shares of worth $5.84 million. And as of 2024-06-30, it was holding 5.883 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 2.14 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.7816 of outstanding shares, having a total worth of $4.74 million.
